Search Results - "Xu, Chong-Rui"

Multiple Primary Lung Cancer With Driver Gene Mutations: Is Targeted Therapy Always the Optimal Choice?—A Case Report.

Authors: Ren, Zi‐Rui Wu, Lv Lu, Chang et al.

Source: Thoracic Cancer. Jan2026, Vol. 17 Issue 1, p1-5. 5p.

Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial.

Authors: Wu, Yi-Long Xu, Chong-Rui Hu, Cheng-Ping et al.

Source: OncoTargets & Therapy. Nov2018, Vol. 11, p8575-8587. 13p.

A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001).

Authors: Chen, Hua-Jun Tu, Hai-Yan Hu, Yanping et al.

Source: Journal of Hematology & Oncology. 1/5/2025, Vol. 18 Issue 1, p1-10. 10p.

Correlation of distribution characteristics and dynamic changes of gut microbiota with the efficacy of immunotherapy in EGFR-mutated non-small cell lung cancer.

Authors: Luo, Wei-Chi Mei, Shi-Qi Huang, Zi-Jian et al.

Source: Journal of Translational Medicine. 4/2/2024, Vol. 22 Issue 1, p1-13. 13p.

Patterns of failure and the subsequent treatment after progression on first-line immunotherapy monotherapy in advanced non-small cell lung cancer: a retrospective study.

Authors: Deng, Jia-Yi Yang, Ming-Yi Yang, Xiao-Rong et al.

Source: BMC Cancer. 9/27/2024, Vol. 24 Issue 1, p1-11. 11p.

Identification of a risk score model based on tertiary lymphoid structure‐related genes for predicting immunotherapy efficacy in non‐small cell lung cancer.

Authors: Mei, Shi‐Qi Liu, Jia‐Qi Huang, Zi‐Jian et al.

Source: Thoracic Cancer. May2024, Vol. 15 Issue 14, p1119-1131. 13p.

Association of COVID-19 and Lung Cancer: Short-Term and Long-Term Interactions.

Authors: Peng, Ying-Long Wang, Zi-Yan Zhong, Ri-Wei et al.

Source: Cancers. Jan2024, Vol. 16 Issue 2, p304. 12p.

EGFR mutations in early‐stage and advanced‐stage lung adenocarcinoma: Analysis based on large‐scale data from China.

Authors: Pi, Can Xu, Chong‐Rui Zhang, Ming‐feng et al.

Source: Thoracic Cancer. Jul2018, Vol. 9 Issue 7, p814-819. 6p.

Heterogeneity of the resistance to gefitinib treatment in a non-small cell lung cancer patient with active epidermal growth factor receptor mutation.

Authors: Xu, Chong ‐ Rui Zhong, Wen ‐ Zhao Zhou, Qing et al.

Source: Thoracic Cancer. Jan2017, Vol. 8 Issue 1, p51-53. 3p.

An Autologous Therapeutic Dendritic Cell Vaccine Transfected with Total Lung Carcinoma RNA Stimulates Cytotoxic T Lymphocyte Responses Against Non-Small Cell Lung Cancer.

Authors: Wang, Kun Zhou, Qing Guo, Ai-Lin et al.

Source: Immunological Investigations. Oct2009, Vol. 38 Issue 7, p665-680. 16p. 1 Color Photograph, 1 Black and White Photograph, 2 Charts, 4 Graphs.

Prognostic and therapeutic significance of circulating tumor cells in patients with lung cancer.

Authors: Yousefi, Meysam Ghaffari, Parisa Nosrati, Rahim et al.

Source: Cellular Oncology (2211-3428). Feb2020, Vol. 43 Issue 1, p31-49. 19p.

Feasibility of computed tomography-guided core needle biopsy in producing state-of-the-art clinical management in Chinese lung cancer.

Authors: Chen, Hua‐Jun Yang, Jin‐Ji Fang, Liang‐Yi et al.

Source: Thoracic Cancer. Mar2014, Vol. 5 Issue 2, p155-161. 7p.

High expression of truncated GLI3 is associated with poor overall survival in patients with non-small cell lung cancer.

Authors: Bai, Xiao-Yan Lin, Jia-Ying Zhang, Xu-Chao et al.

Source: Cancer Biomarkers. 2013, Vol. 13 Issue 1, p37-47. 11p.

Volume 19 Author Index.

Source: The oncologist Dec2014; Vol. 19 (12).

Journal Info: Publisher: Oxford University Press / USA ISSN: 1083-7159

Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy.

Authors: Lim, Zuan-Fu Ma, Patrick C.

Source: Journal of Hematology & Oncology. 12/9/2019, Vol. 12 Issue 1, pN.PAG-N.PAG. 1p.